Skadden, Arps, Slate, Meagher & Flom has advised Shanghai-based biopharmaceutical company JHBP (CY) Holdings, a holding company for Genor Biopharma,  on its HK $2.87 billion ($371 million) IPO in Hong Kong, with Kirkland & Ellis representing the joint sponsors and the underwriters.

Founded in 2007, Genor is a biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs The public offering was oversubscribed 1,247 times, making it one of the most sought-after biotech IPOs in Hong Kong this year.

The offering is part of a recent flurry of IPOs and secondary listings worth at least $4.5 billion currently being launched in Hong Kong, with Reuters reporting that 2020 is on track to be the second-busiest year for equity capital markets in the city. Recently, Chinese companies Yum China Holdings, Zai Lab and ZTO Express undertook successful secondary listings on HKEX while Ming Yuan Cloud Group went public in Hong Kong.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

Skadden, AMT, MHM, Davis Polk advise on Trial Holding’s $258 mln Japan IPO

by Nimitt Dixit |

Skadden, Arps, Slate, Meagher & Flom and Anderson Mori & Tomotsune have advised Japanese discount-store chain operator Trial Holdings on its $258 million initial public offering on the Tokyo Stock Exchange (TSE), the largest IPO of the year so far.

Deals

Skadden, Hogan Lovells guide $1 bln TDCX take-private deal

by Nimitt Dixit |

U.S. law firm Skadden, Arps, Slate, Meagher & Flom has advised billionaire Laurent Junique, the founder and CEO of TDCX, in his move to take the company private at an equity valuation of approximately $1.037 billion.

Deals

Top Indian firms, Skadden, Cleary on $8.5 bln Disney-Reliance merger

by Nimitt Dixit |

Skadden, Arps, Slate, Meagher & Flom, Khaitan & Co, and Shardul Amarchand Mangaldas & Co are advising Reliance Industries and its media subsidiary Viacom18 on a planned $8.5 billion media merger with Walt Disney’s Star India.